Form 4: Cytosorbents CEO Chan Receives Equity Awards

Cytosorbents Corporation's CEO, Phillip P. Chan, was granted 105,600 restricted stock units and 136,400 stock options as part of his compensation.

Summary

• Phillip P. Chan, CEO and Director of Cytosorbents Corp, was granted 105,600 Restricted Stock Units (RSUs) and 136,400 stock options on August 8, 2025.
• The RSUs were granted at a price of $0 and will vest in equal parts on the first and second year anniversaries of the grant date, contingent on continued service.
• The stock options have an exercise price of $1 and will vest over three years: 50% on the first anniversary, 25% on the second, and 25% on the third, also subject to continued service.
• Following these transactions, Mr. Chan beneficially owns 1,382,963 shares of common stock and 136,400 stock options.
• His total beneficial ownership includes previously granted RSUs (10,300, 18,700, 57,000, 130,000) that vest upon a "Change In Control," and 48,000 unvested RSUs from an April 2, 2024 grant.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of executive compensation, which is generally a neutral to slightly positive event as it aligns management incentives with shareholder interests, though it introduces potential future dilution.

Positives

• Grant of equity awards aligns management's interests with shareholder value creation.
• The vesting schedule encourages long-term commitment from the CEO.

Negatives

• The issuance of new equity awards could lead to potential future dilution for existing shareholders upon vesting and exercise.

Future Outlook

NA

Industry Context

NA

Corporate Governance

Stakeholder Impact

• Shareholders: Potential future dilution from the vesting and exercise of RSUs and stock options. However, it also signals management's continued commitment and alignment with long-term company performance.

Next Steps

• Vesting of 105,600 RSUs on the first and second year anniversaries of August 8, 2025.
• Vesting of 136,400 stock options over three years (50% on 1st, 25% on 2nd, 25% on 3rd anniversary of August 8, 2025).
• Continued filing of Forms 3, 4, and 5 by Peter J. Mariani on behalf of Phillip P. Chan as per the Power of Attorney.

Key Dates

Recommendation

This Form 4 filing details a routine grant of equity compensation to the CEO, which is a standard practice for executive incentive alignment and does not present new information that would warrant a change in investment thesis. The transaction itself is not indicative of significant positive or negative operational changes or financial performance, thus a 'hold' recommendation is appropriate as it maintains current positioning based on existing company fundamentals.

Keywords

Cytosorbents Corp, CTSO, Phillip P. Chan, SEC Form 4, Insider Trading, Restricted Stock Units, Stock Options, Executive Compensation, Equity Awards